WCLC 2023 | Multidisciplinary consensus for the definition of resectable NSCLC

Mariana Brandao, MD, PhD, Institute Jules Bordet, Brussels, Belgium, discusses the current consensus on the definition of resectable stage III non-small cell lung cancer (NSCLC). In recent years, multiple clinical trials have been conducted to examine the neoadjuvant combination of chemotherapy and immunotherapy for patients with NSCLC. A frequent difficulty in these trials is the lack of definition for resectable tumours and the European Organisation for Research and Treatment of Cancer (EORTC) Lung Cancer Group proposed the development of a multidisciplinary consensus to classify resectable NSCLC. Data was collected through an international survey, a systematic literature review, and over 100 cases of patients with stage III NSCLC for clinicians to review. The main findings of the consensus indicated that certain critical structures such as the oesophagus are completely unresectable, and tumours with limited lymph node involvement (such as N1 and N0 tumours) are resectable. Dr Brandao shared that the goal of this consensus is to improve inclusion criteria in trials and facilitate the application of results to clinical practice. This interview took place at the 2023 World Conference on Lung Cancer (WCLC) in Singapore, Singapore.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.